William Blair Has Negative Estimate for IQVIA Q3 Earnings

Key Points

• William Blair has cut its Q3 2025 earnings estimate for IQVIA to $2.66 per share, slightly down from a previous estimate of $2.67, while maintaining an "Outperform" rating on the stock.
• Several analysts have adjusted their price targets on IQVIA, with Truist Financial increasing its target to $235.00, while HSBC downgraded it to $160.00.
• IQVIA's latest earnings report showed $2.81 EPS for the quarter, surpassing analysts' expectations of $2.77, along with a revenue of $4.02 billion, up 5.3% from the same quarter last year.

IQVIA Holdings Inc. (NYSE:IQV - Free Report) - Investment analysts at William Blair decreased their Q3 2025 earnings per share (EPS) estimates for IQVIA in a report issued on Wednesday, July 23rd. William Blair analyst M. Smock now anticipates that the medical research company will earn $2.66 per share for the quarter, down from their prior forecast of $2.67. William Blair has a "Outperform" rating on the stock. The consensus estimate for IQVIA's current full-year earnings is $10.84 per share.

A number of other research analysts have also issued reports on IQV. Mizuho set a $225.00 target price on IQVIA and gave the company an "outperform" rating in a research report on Friday. Truist Financial raised their price objective on IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Redburn Partners set a $188.00 price objective on IQVIA in a report on Friday, May 23rd. UBS Group raised their price objective on IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Finally, Robert W. Baird raised their price objective on IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Seven equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $228.62.

IQVIA Price Performance

Shares of NYSE:IQV traded up $1.04 during midday trading on Friday, reaching $200.21. 613,953 shares of the company's stock traded hands, compared to its average volume of 2,033,214. IQVIA has a 1 year low of $134.65 and a 1 year high of $252.88. The company has a market cap of $34.03 billion, a P/E ratio of 29.02, a PEG ratio of 2.18 and a beta of 1.30. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The company has a fifty day simple moving average of $157.09 and a two-hundred day simple moving average of $170.04.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The business had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same quarter in the prior year, the firm posted $2.64 EPS. The business's quarterly revenue was up 5.3% compared to the same quarter last year.

Insider Activity

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider directly owned 27,178 shares of the company's stock, valued at $5,165,178.90. The trade was a 17.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider directly owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.

Hedge Funds Weigh In On IQVIA

A number of institutional investors and hedge funds have recently made changes to their positions in IQV. American National Bank & Trust acquired a new position in shares of IQVIA during the first quarter worth about $26,000. Clal Insurance Enterprises Holdings Ltd grew its position in shares of IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after buying an additional 131 shares in the last quarter. Golden State Wealth Management LLC grew its position in shares of IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after buying an additional 130 shares in the last quarter. AllSquare Wealth Management LLC acquired a new position in shares of IQVIA during the first quarter worth about $33,000. Finally, ST Germain D J Co. Inc. grew its position in shares of IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after buying an additional 76 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.